Effects of Aspirin Treatment on Fibrin Network Formation in Patients With Type 1 Diabetes

• Status: Completed
• Trial end date: 2011-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The fibrin network is an important component of an arterial thrombus and its structure influences the degradation of the formed clot. A tighter and less permeable fibrin network, which is less susceptible to fibrinolysis, is formed in patients with manifest cardiovascular disease (CVD) or conditions associated with increased risk of atherothrombotic complications. In a previous study we have shown reduced fibrin network permeability in patients with type 1 diabetes, which may contribute to their increased risk of CVD. Low dose aspirin treatment is standard in management of CVD; however, the effect seems reduced in patients with diabetes. Our previous studies have shown that aspirin treatment alters the fibrin network in non-diabetic individuals and increases the fibrin network permeability. The effect of aspirin on fibrin network formation in patients with diabetes is unclear.

We hypothesized that patients with type 1 diabetes might need higher doses of aspirin than the recommended low dose (75mg) treatment to gain effects on fibrin network permeability, and that the effects of aspirin treatment on fibrin network in these patients are influenced by the glycemic control.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Karolinska Institutet
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Diabetes mellitus, type 1

• Levels of HbA1C (glycated hemoglobin) <7.4% (NGSP standard)

• Levels of HbA1C >8.4% (NGSP standard)

Exclusion Criteria:

• Prior aspirin treatment

• Treatment with anticoagulant drugs

• Ongoing treatment with NSAIDs or other antiplatelet drugs

• A history of macrovascular disease